ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer
Authors:
- Ken André OlaussenKOKen André Olaussen
- Giannis MountziosGMGiannis Mountzios
- Jean-Charles SoriaJSJean-Charles Soria
- 1 July 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 13 (4) , 284-289
Abstract
Cisplatin-based chemotherapy remains the treatment of choice in advanced nonsmall-cell lung cancer. The development of predictive biomarkers able to identify lung-cancer patients who are most likely to benefit from cisplatin-based chemotherapy would be a powerful tool. Many reports have explored the role of ERCC1 expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells. Using immunohistochemistry in resected tumors, the International Adjuvant Lung Cancer Trial showed that high ERCC1 protein expression was associated with improved survival in patients who did not receive chemotherapy. In contrast, the benefit of adjuvant cisplatin-based chemotherapy was more profound in patients with low ERCC1 expression. Other investigators studying mRNA expression in tumor biopsies from patients treated with cisplatin and gemcitabine showed that patients with low ERCC1 mRNA expression have a longer median survival compared to those with high expression. High ERCC1 expression is predictive of resistance to platinum-based therapy. Thus, there is solid evidence to support ERCC1 as a useful marker of clinical resistance to platinum-based chemotherapy in the adjuvant setting of nonsmall-cell lung cancer. Meanwhile, optimization of methodology and standardization of technical procedures seem necessary before larger prospective studies can address the same question.Keywords
This publication has 41 references indexed in Scilit:
- A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung CancerJournal of Thoracic Oncology, 2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Chemotherapy for advanced lung cancerEuropean Journal of Cancer, 2004
- Multidisciplinary Management of Lung CancerNew England Journal of Medicine, 2004
- Mechanism of open complex and dual incision formation by human nucleotide excision repair factorsThe EMBO Journal, 1997
- Reaction Mechanism of Human DNA Repair Excision NucleaseJournal of Biological Chemistry, 1996
- Repair of Cisplatin−DNA Adducts by the Mammalian Excision NucleaseBiochemistry, 1996
- Mechanisms of DNA Excision RepairScience, 1994
- Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.Journal of Clinical Investigation, 1994
- ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 1992